MetaCap

Aura Biosciences (AURA) vs Immatics N.V. (IMTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Aura Biosciences (AURA) has outperformed Immatics N.V. (IMTX) over the past year, gaining 26.3% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -69.6% for AURA. Immatics N.V. is the larger company by market cap ($878.6 million vs $715.0 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AURA+26.29%IMTX-43.43%
+69%+10%-49%
Nov 21, 20251 yearNov 20, 2026
AURA-69.47%IMTX-51.47%
+18%-32%-82%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AURA versus IMTX key metrics
MetricAURAIMTX
Share price$6.87$5.77
Market cap$714.99M$878.58M
1-day change-1.58%-3.03%
YTD return+26.06%-45.05%
1-year return+26.29%-43.43%
5-year return-69.63%-48.57%
EPS (TTM)$-1.59$-1.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-106.19M—
52-week high$9.54$12.41
52-week low$4.73$5.72
Distance from 52-week high-27.95%-53.51%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+141.63%+176.78%
Average volume847.22K962.74K
Shares outstanding104.07M152.27M
Employees113721
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AURA has outperformed IMTX by 69.7 percentage points over the past year.

About Aura Biosciences

AURA stock →

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees

About Immatics N.V.

IMTX stock →

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees

AURA vs IMTX FAQ

Which is bigger, Aura Biosciences or Immatics N.V.?

Immatics N.V. (IMTX) is larger, with a market capitalization of $878.58M compared with $714.99M for Aura Biosciences (AURA).

Which stock has performed better over the past year, AURA or IMTX?

AURA returned +26.29% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.

Are Aura Biosciences and Immatics N.V. in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons